Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients

Oncology Reports

Volumn 18, Issue 6, 2007, Pages 1521-1527

  Fortunati, Nicoletta ^a   Manti, Roberta ^a   Birocco, Nadia ^a   Pugliese, Mariateresa ^a   Brignardello, Enrico ^a   Ciuffreda, Libero ^a   Catalano, Maria G ^b   Aragno, Manuela ^b   Boccuzzi, Giuseppe ^a,b  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Cachexia; Cytokines; Lung cancer; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CYTOKINE; GLUTATHIONE; INTERLEUKIN 6; NITRATE; NITRITE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANOREXIA; ARTICLE; BLOOD; CACHEXIA; FEMALE; GENETICS; HUMAN; INFLAMMATION; LUNG TUMOR; MALE; MIDDLE AGED; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WEIGHT REDUCTION;

AGED; ANOREXIA; ANTIOXIDANTS; CACHEXIA; CYTOKINES; FEMALE; GLUTATHIONE; HUMANS; INFLAMMATION; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; MIDDLE AGED; NITRATES; NITRITES; OXIDATIVE STRESS; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN E; WEIGHT LOSS;

EID: 38449085115     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.6.1521     Document Type: Article

References (43)

1. Inui A: Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52: 72-91, 2002.
2. MacDonald N, Easson AM, Mazurak VC, Dunn GP and Baracos VE: Understanding and managing cancer cachexia. J Am Coll Surg 197: 143-161, 2003. (Pubitemid 36759189)
3. Muscaritoli M, Bossola M, Aversa Z, Bellantone R and Rossi Fanelli F: Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 42: 31-41, 2006. (Pubitemid 41814530)
4. Argilés JM, Busquets S, Garcìa-Martìnez C and Lòpez-Soriano FJ: Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition 21: 977-985, 2005.
5. Argilés JM, Busquets S and Lòpez-Soriano FJ: The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol 37: 2036-2046, 2005.
6. Tisdale MJ: Molecular pathways leading to cancer cachexia. Physiol 20: 340-348, 2005.
7. Rossi Fanelli F, Cangiano C, Muscaritoli M, Conversano L, Torelli GF and Cascino A: Tumour-induced changes in host metabolism: a posible marker of neoplatic disease. Nutrition 11: 595-600, 1995. (Pubitemid 26006232)
8. Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, Pacelli F, Rossi Fanelli F, Doglietto GB and Baccino FM: Increased muscle proteasome activity correlates with disease severità in gastric cancer patients. Ann Surg 237: 384-389, 2003. (Pubitemid 38176454)
9. Savarese DM, Hsieh C and Stewart FM: Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumours. J Clin Oncol 15: 2981-2995, 1997. (Pubitemid 27330027)
10. Deans C and Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8: 265-269, 2005. (Pubitemid 40586184)
11. Macri A, Versaci A, Loddo S, Scuderi G, Travagliante M, Trimarchi G, Teti D and Famulari C: Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers 11: 184-193, 2006. (Pubitemid 43772015)
12. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr and Corey E: Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97: 1211-1216, 2003. (Pubitemid 36237306)
13. Iwase S, Murakami T, Saito Y and Nakagawa K: Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur Cytokine Netw 15: 312-316, 2004. (Pubitemid 40127655)
14. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL and Kurzrock R: Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101: 2727-2736, 2004. (Pubitemid 39603180)
15. Kaminska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, Michalski W and Chechlinska M: Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumour necrosis factor receptor type I-an independent prognostic factor. Tumour Biol 26: 186-194, 2005. (Pubitemid 41379744)
16. Mantovani G, Maccio A, Melis G, Mura L, Massa E and Mudu MC: Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. Int J Cancer 86: 842-847, 2000. (Pubitemid 30350200)
17. Kayacan O, Karnak D, Beder S, Gullu E, Tutkak H, Senler FC and Koksal D: Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol 29: 328-335, 2006. (Pubitemid 44197536)
18. Barreiro E, de la Puente B, Busquets S, Lopez-Soriano FJ, Gea J and Argiles JM: Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett 579: 1646-1652, 2005. (Pubitemid 40341537)
19. Busquets S, Almendro V, Barreiro E, Figueras M, Argiles JM and Lopez-Soriano FJ: Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett 579: 717-722, 2005.
20. Mantovani G, Maccio A, Madeddu C, Mura L, Massa E, Gramignano G, Lusso MR, Murgia V, Camboni P and Ferreli L: Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J Cell Mol Med 6: 570-582, 2002. (Pubitemid 44146435)
21. Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, Lusso MR, Massa E, Mocci M and Serpe R: Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med 81: 664-673, 2003. (Pubitemid 37357681)
22. Catalano MG, Fortunati N, Arena K, Costelli P, Aragno M, Danni O and Boccuzzi G: Selective up-regulation of tumour necrosis factor receptor I in tumour-bearing rats with cancer-related cachexia. Int J Oncol 23: 429-436, 2003.
23. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987. (Pubitemid 17064313)
24. Moshage H, Kok B, Huizenga JR and Jansen PL: Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 41: 892-896, 1995.
25. Esterbauer H, Koller E, Slee RG and Koster JF: Possible involvement of the lipid-peroxidation product 4-hydroxynonenal in the formation of fluorescent chromolipids. Biochem J 239: 405-409, 1986. (Pubitemid 16008460)
26. Esterbauer H, Schaur RJ and Zollner H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128, 1991. (Pubitemid 121003917)
27. Ravindranath V: Animal models and molecular markers for cerebral ischemia-reperfusion injury in brain. Methods Enzymol 233: 610-619, 1994.
28. Owens CW and Belcher RV: A colorimetric micro-method for the determination of glutathione. Biochem J 94: 705-711, 1965.
29. Burton GW, Webb A and Ingold KU. A mild, rapid, and efficient method of lipid extraction for use in determining vitamin E/lipid ratios. Lipids 20: 29-39, 1985. (Pubitemid 15168820)
30. Fernia RA and Goyette R: The science of megestrol acetate delivery: potential to improve outcomes in cachexia. BioDrugs 19: 179-187, 2005.
31. May PE, Barber A, D'Olimpio JT, Hourihane A and Abumrad NN: Reversal of cancer related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine. Am J Surg 183: 471-479, 2002. (Pubitemid 34442515)
32. Bing C, Russel ST, Beckett EE, Collins P, Taylor S, Barraclough R, Tisdale MJ and Wlliams G: Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived-lipid-mobilizing factor. Br J Cancer 86: 612-618, 2002. (Pubitemid 34185100)
33. Mantovani G, Maccio A, Madeddu C, Gramignao G, Lusso MR, Serpe R, Massa E, Astara G and Deiana L: A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, pogestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 15: 1030-1034, 2006. (Pubitemid 43823535)
34. Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, Chechlinska M and Steffen J: Preteratment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlation with clinicopathological features and prognosis. M-CSF- an independent prognostic factor. Oncology 70: 115-125, 2006. (Pubitemid 43760337)
35. Aleman MR, Santolaria F, Batista N, de La Vega M, Gonzalez-Reimers E, Milena A, Llanos M and Gomez-Sirvent JL: Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 19: 21-26, 2002.
36. Barber MD, Fearon KC and Ross JA: Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci 99: 83-87,1999. (Pubitemid 29045868)
37. Shibata M, Takekawa M and Amano S: Increased serum concentrations of soluble tumour necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer. Surg Today 28: 884-888, 1998. (Pubitemid 28433623)
38. Figueras M, Busquets S, Carbo N, Almendro V, Argiles JM and Lopez-Soriano FJ: Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue. Int J Oncol 27: 855-860, 2005.
39. Iwase S, Murakami T, Saito Y and Nakagawa K: Sleep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur Cytokine Netw 15: 312-318, 2004.
40. Diament MJ, Peluffo GD, Stillitani I, Cerchietti LC, Navigante A, Ranuncolo SM and Klein SM: Inhibition of tumour progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin. Cancer Invest 24: 126-131, 2006.
41. Valko M, Rhodes CJ, Moncol J, Izakovic M and Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160: 1-40, 2006. (Pubitemid 43227479)
42. Engel RH and Evens AM: Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci 11: 300-312, 2006. (Pubitemid 43253493)
43. Klaunig JE and Kamendulis LM: The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44: 239-267, 2004. (Pubitemid 38263841)